cefixime has been researched along with sulfamethoxazole in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Kelly, KJ; Kumar, A | 1 |
| Chin, NX; Neu, HC | 1 |
| Mulligan, ME | 1 |
| Brink, G; Fourie, S; Levenstein, J; Michaelides, B; Murray, E; Naidoo, N; Summerfield, PJ | 1 |
| Puéchal, X | 1 |
| Akbar, N; Jabri, T; Kawish, M; Khan, NA; Shah, MR; Siddiqui, R | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chatre, P; Delmas, JM; Faure, S; Laurentie, M; Perrin-Guyomard, A | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 review(s) available for cefixime and sulfamethoxazole
| Article | Year |
|---|---|
[Whipple's disease].
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Cefixime; Female; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Middle Aged; Polymerase Chain Reaction; Recurrence; Sex Factors; Sulfamethoxazole; Time Factors; Trimethoprim; Tropheryma; Whipple Disease | 2009 |
1 trial(s) available for cefixime and sulfamethoxazole
| Article | Year |
|---|---|
Comparison of cefixime and co-trimoxazole in acute uncomplicated urinary tract infection. A double-blind general practice study.
Topics: Adult; Aged; Anti-Bacterial Agents; Cefixime; Cefotaxime; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Escherichia coli; Female; Humans; Male; Middle Aged; Proteus mirabilis; Random Allocation; Staphylococcus aureus; Staphylococcus epidermidis; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 1986 |
14 other study(ies) available for cefixime and sulfamethoxazole
| Article | Year |
|---|---|
In vitro activity of cefixime (CL284635) and other antimicrobial agents against Haemophilus isolates from pediatric patients.
Topics: Anti-Bacterial Agents; Cefixime; Cefotaxime; Child; Drug Combinations; Haemophilus Infections; Haemophilus influenzae; Humans; Infant; Microbial Sensitivity Tests; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1988 |
In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lactamases; Cefaclor; Cefixime; Cefotaxime; Cefpodoxime; Ceftizoxime; Cefuroxime; Cephalexin; Cephalosporins; Clavulanic Acids; Culture Media; Drug Combinations; Drug Stability; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1988 |
In vitro activity of cefixime and six other agents against nosocomial pathogens of the Enterobacteriaceae family.
Topics: Ampicillin; Anti-Bacterial Agents; Cefaclor; Cefixime; Cefotaxime; Cephalothin; Cross Infection; Drug Combinations; Enterobacteriaceae; Enterobacteriaceae Infections; Gentamicins; Humans; Microbial Sensitivity Tests; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1987 |
Enhancing efficacy of existing antibacterials against selected multiple drug resistant bacteria using cinnamic acid-coated magnetic iron oxide and mesoporous silica nanoparticles.
Topics: Anti-Bacterial Agents; Cefixime; Cinnamates; Escherichia coli; Ferric Compounds; Humans; Lactate Dehydrogenases; Magnetic Phenomena; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Nanoparticles; Prospective Studies; Silicon Dioxide; Sulfamethoxazole | 2022 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cefixime; Chromatography, High Pressure Liquid; Conjugation, Genetic; Culture Media; Enterobacteriaceae; Escherichia coli; Escherichia coli Proteins; Feces; Female; Humans; Intestines; Male; Mass Spectrometry; Mice; Mice, Inbred C3H; Microbial Sensitivity Tests; Plasmids; Rats; Salmonella enterica | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |